SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

An alleged early leak of Phase 3 results for Moderna and Mercks personalized melanoma vaccine triggered a sharp selloff ahead of the full data presentation. Traders disagree over whether the reported benefit is clinically meaningful but fell short of elevated expectations, and some question the leaks accuracy while others expect more volatility around the full readout.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCXs sharp pullback after its earnings-driven jump is being attributed mainly to a large share unlock that traders fear will add selling pressure, alongside broader tech weakness and concerns about heavy spending and a possible Tesla tie-up. The earnings beat has not eased the bearish reaction, though some investors view the decline as a buying opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp selloff in semiconductor and technology stocks has pushed SOXL to a six-month low, with its 3x daily leverage amplifying the decline. Traders are split between seeing AI-funding concerns and broader market pressure as signs of further downside, and treating the drop as an oversold buying opportunity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp tech-led selloff, with traders focused on worries about AI spending and credit availability, weakness in semiconductors, and elevated oil prices tied to Iran tensions. The conversation is largely bearish, though some traders see an oversold dip-buying opportunity or expect a rebound.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

AMZNs sharp decline is being discussed largely alongside selling across mega-cap tech and hyperscalers, with traders also questioning whether heavy AI and data-center spending could pressure cash flow ahead of earnings. Reactions are split between dip buyers calling the drop excessive and bearish traders anticipating further weakness; no single confirmed company-specific catalyst dominates.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations and AI/cloud demand surged, but shares sold off sharply as traders focused on negative free cash flow, a lower cash-conversion outlook, higher restructuring costs and supply-chain cost pressure. Bulls call the reaction an overreaction and point to AI and network growth, while bears argue cash generation and the outlook matter more than the headline beat.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas sharp selloff after its quarterly results is being linked to rising AI infrastructure spending, negative free cash flow, and concerns that the new nonvoting share class could enable future fundraising and dilute shareholders, despite strong advertising performance and upbeat guidance. Traders are split between viewing the drop as a buying opportunity and questioning whether AI investments can generate enough returns to justify the costs.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention after a sharp month-long slide amid weakness across semiconductor and AI stocks, with traders also focused on its test of the 200-day moving average and upcoming earnings. Some view the selloff as an oversold buying opportunity near support, while others warn that the decline could continue; the cause is not settled in the discussion.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgents CFO departure, with finance executive Amy Ard taking over, is driving the sharp selloff and concerns among traders that the change could signal undisclosed financial problems; those concerns remain speculation. The community is split between calling the decline an overreaction and buying on the companys data-center and power-grid growth prospects, and waiting for management to clarify the situation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a sharp semiconductor and tech selloff, alongside broader Nasdaq weakness, as traders debate stretched AI valuations, data-center spending returns, and macro risks. Some see the decline as an oversold dip-buying opportunity ahead of earnings, while others warn of a deeper AI-sector correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences: Stifel...

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026. Participants...

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround 

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. 2026 continues to be an important year of...

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As...

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the...

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The company said that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in certain patients with Sézary syndrome and Mycosis fungoides.</li><li>The primary goal of the study is to gauge progression-free survival.&nbsp;</li><li>The FDA reviewed the protocol of the trial with no further comments, the company further noted.&nbsp; &nbsp;</li></ul>Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Symptoms include patches, plaques, or tumors on the skin that can be itchy and may resemble eczema or psoriasis.<h2 class="st-heading-2">About the Late-Stage Confirmatory Trial</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251109757297/en/Innate-Pharma-Announces-FDA-Clearance-to-Proceed-With-TELLOMAK-3-a-Confirmatory-Phase-3-Trial-of-Lacutamab-in-CTCL">said</a> that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in patients with Sézary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. Both Sézary syndrome and Mycosis fungoides are types of cutaneous T-cell lymphomas.The primary goal of the study is to gauge progression-free survival or the length of time a patient lives with a disease, such as cancer, without it getting worse, which can include time when the cancer is stable or cured.The company now intends to initiate the confirmatory trial in the first half of 2026. The FDA reviewed the protocol of the trial with no further comments, the company further noted.In a mid-stage trial, Lacutamab demonstrated durable activity, a favorable safety profile, and improvements in patients’ quality of life.“...this milestone brings us one step closer to our next goal, submitting for accelerated approval in Sézary syndrome once the Phase 3 trial is underway,” CEO Jonathan Dickinson said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IPHA">IPHA stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="data:image/png;base64,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" width="623" height="63" alt="IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the stock under $3.<stembedurl>https://stocktwits.com/Iiii1ii/message/635561240</stembedurl>Another cheered the news as significant and positive.<stembedurl>https://stocktwits.com/StockNews_Live/message/635557846</stembedurl>IPHA stock is down by 4% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/us-lawmakers-reportedly-urge-ceo-to-end-union-busting-practices/cLPcLtxREcz">Starbucks Faces Political Heat: US Lawmakers Reportedly Urge CEO To End 'Union Busting’ Practices</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.

The company now intends to initiate the confirmatory trial in the first half of 2026.


Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Innate Pharma

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits Polls

$IPHA in the middle of Nov we should be receive big news do your research on this one can be very big

Neo55

$IPHA Does this thing have a pulse?  30 min in and 5k shares on a 1.50 stock.   NP. Much LOVE for FRANCE.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPHA Innate Pharma

Fundamentals

Latest IPHA News